Grant Life Sciences Expects To Begin Generating Revenues From Sales Of Its Rapid Tests For Malaria And Dengue Fever Before Year's End

Grant Life Sciences (OTC Bulletin Board: GLIF - News) announced today that it expects to begin generating revenues this year, possibly within 30 days, on sales of its rapid tests for Malaria and Dengue Fever. These products, along with rapid tests for HIV-1 and HIV-2, were acquired earlier this year from AccuDx Corp., a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics. (Dr. Pottahil was the section manager for retroviruses and tumor markers and PCR diagnostics at Hoffman-La Roche from 1985 to 1992, when he co-founded Specialty BioSystems with Specialty Laboratories, one of the largest independent reference laboratories in California. Dr. Pottathil also was an advisor to the World Health Organization's Sexually Transmitted Diseases and Global Vaccination program.)